Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Completed 1Active not recruiting 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Head & Neck 2

Conditions

Recurrence 2Neoplasm Metastasis 2Nasopharyngeal Carcinoma 2Triple Negative Breast Neoplasms 1Small Cell Lung Carcinoma 1Carcinoma, Non-Small-Cell Lung 1

Interventions

pembrolizumab 45Specimen Handling 45Biopsy 37Magnetic Resonance Spectroscopy 36Paclitaxel 22Nivolumab 21Carboplatin 21Gemcitabine 20Radiosurgery 18Irinotecan 16Ipilimumab 13Cisplatin 13Capecitabine 12130-nm albumin-bound paclitaxel 12trastuzumab deruxtecan 11Taxes 11Pemetrexed 11Cetuximab 11olaparib 10Leucovorin 10Fluorouracil 10Cyclophosphamide 10durvalumab 9Oxaliplatin 9Bevacizumab 9abemaciclib 8X-Rays 8Fulvestrant 8Drug Therapy 8palbociclib 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Neoplasm Metastasis × 18-O-demethylcervinomycin A2 × 90 days × Clear all
NCT05294172 2026-05-08

KL-A167 Injection Combined With Cisplatin and Gemcitabine vs Placebo Combined With Cisplatin and Gemcitabine in the Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

Phase 3 Active not recruiting
295 enrolled
Head & Neck

Nasopharyngeal Carcinoma, Neoplasm Metastasis, Recurrence

NCT03848286 2026-05-05

KL-A167 Injection in Recurrent or Metastatic Nasopharyngeal Carcinoma

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

Phase 2 Completed
153 enrolled
Head & Neck

Nasopharyngeal Carcinoma, Neoplasm Metastasis, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡